Comparison

Thymogen vs Thymosin Alpha-1

Thymogen is the ultra-short, precision immune reboot; Thymosin Alpha-1 is the long-acting, clinically validated immune recalibrator.

Effectiveness Profile

Thymogen
Thymosin Alpha-1

At a Glance

 ThymogenThymosin Alpha-1
TypeOtherHealing Peptide
Legal statusResearchResearch
Half-lifeMinutes (plasma); immunological effects persist for days–weeks post-course~2 hours (plasma); biological effects persist days
Preferred routeSubQSubQ
Dose frequencyonce-dailytwice-weekly
Beginner dose100–100 mcg1.6–1.6 mg
Intermediate dose100–200 mcg1.6–1.6 mg
Advanced dose500–1000 mcg1.6–1.6 mg
Cycle length1–2 wks4–12 wks
Bioavailability90%
Time to peak0.25h1.5h
Active duration24h24h
Storage2–8°C refrigerated; stable ~30 days reconstituted2–8°C refrigerated; stable 4–6 weeks reconstituted
PCT requiredNoNo
Ancillaries requiredNoNo
Safe for womenYesYes

Verdict

Thymogen wins for precise, short-term immune normalization (7–14 day pulses), fast onset for post-blast/crash recovery, and minimal systemic disruption—ideal for users needing a rapid thymic reset without running a full peptide course. Easier sourcing as a research dipeptide, ultralow dosing makes it cost-effective for short cycles.

Thymosin Alpha-1 wins for depth and breadth: robust clinical anti-viral and anti-tumor data, sustained modulation of both innate and adaptive immunity, and a well-tolerated long-term profile. Superior for chronic or complex immune dysregulation, immunosenescence, or stacking into multi-month protocols.

Pick A or B?

Pick Thymogen if:

  • The protocol calls for a rapid immune reboot after heavy AAS, prep, or illness
  • Quarterly or perioperative thymic support is needed without a long peptide course
  • A short, bioregulator-style 7–14 day cycle is preferred
  • The research scenario prioritizes normalization of CD4/CD8 ratios
  • Sourcing/handling ultra-small peptides with low side-effect risk is a plus

Pick Thymosin Alpha-1 if:

  • The goal is broad, well-characterized immune support over weeks/months
  • Viral reactivation, chronic post-infection fatigue, or ICU-grade immune modulation is relevant
  • Immunosenescence or age-related immune decline is a central concern
  • Pairing with BPC-157, TB-500, or deeper peptide stacks over an extended period
  • Preference for a heavily clinically validated research peptide with global approval history

Where to Buy

Swiss Chems

Swiss Chems

Ships from US

Affiliate link — we may earn a commission at no cost to you.

Use code-10%
BioMogging
Real Peptides

Real Peptides

Ships from USLogin Required

Affiliate link — we may earn a commission at no cost to you.

Use code-20%
BioMogging20